Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
supCD7 CART Cell Injection in Relapsed or Refractory CD7 Positive Hematologic Malignancies
NCT07153068Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of UTAA07 in acute myeloid leukemia (AML), T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jun 2025; status: recruiting.
02
Drugs
UTAA07
03
Conditions
acute myeloid leukemia (AML)T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL)
Beyond the preview
Go deeper on NCT07153068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07153068.